The scale of the contamination problem is staggering. The Food and Agriculture Organization has long estimated that about 25 percent of food crops are tainted with mycotoxins, but more recent analyses suggest the true figure may be as high as 60 to 80 percent, a revision driven largely by improvements in analytical sensitivity. On the pesticide front, roughly 3.73 million tonnes of agricultural chemicals were applied globally in 2023, yet only an estimated 0.1 percent of pesticides actually reach their intended targets. The rest disperses into air, water, and soil, eventually threading its way back into the food chain and onto our plates.

The health stakes are far from theoretical. Organophosphate pesticides such as chlorpyrifos, diazinon, and malathion can inflict long-term neurological and psychiatric damage by inhibiting the acetylcholinesterase enzyme. Paraquat exposure is linked to severe skin burns, pulmonary fibrosis, and respiratory failure, while carbamates like carbofuran have been associated with endocrine disruption, reproductive harm, and elevated risk of non-Hodgkin lymphoma. Mycotoxins, including aflatoxins, ochratoxin A, deoxynivalenol, and zearalenone, cause both acute and chronic toxicity and have been detected at alarming rates in staple grains worldwide.

The evidence from market surveys is sobering. In Turkish cereal products, aflatoxin B1 concentrations exceeded regulatory limits in more than a quarter of tested samples. In Pakistan, a study of 229 retail cereal products found that 130 were contaminated with zearalenone, 121 with aflatoxin B1, and 115 with ochratoxin A, with many samples breaching maximum permissible levels. In India, 70 of 117 cereal samples tested positive for zearalenone, and one-third of those exceeded European Union limits. Meanwhile, European Rapid Alert System data show that fruits and vegetables accounted for 67.1 percent of all pesticide residue notifications between 1999 and 2022, with okra, chili peppers, beans, and aubergines showing the highest contamination rates.

Against this backdrop, conventional analytical techniques such as gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry remain the gold standard for accuracy and sensitivity. But they come with serious drawbacks: they are time-consuming, demand toxic organic solvents, require expensive equipment and trained personnel, and are poorly suited to on-site or high-throughput screening. This is precisely the gap that antibody-based sensing platforms are engineered to fill, leveraging the exquisite molecular specificity of antigen-antibody interactions to deliver rapid results with minimal infrastructure.

ELISA, or enzyme-linked immunosorbent assay, has emerged as one of the most versatile of these platforms. Competitive ELISA formats dominate for small-molecule contaminants such as pesticides and mycotoxins, which lack the multiple epitopes needed for sandwich-style detection. Recent innovations are striking. An indirect competitive ELISA developed for the neonicotinoid pymetrozine achieved detection limits between 1.62 and 1.66 micrograms per kilogram in wheat, maize, and rice, matching the sensitivity of liquid chromatography-tandem mass spectrometry at a fraction of the cost and time. Similarly, a direct competitive ELISA for the herbicide metsulfuron-methyl reached an IC50 of 37.03 micrograms per liter with recovery rates between 81 and 102 percent in spiked cereal samples.

Lateral-flow immunoassays, the same technology behind at-home pregnancy tests, push accessibility even further. These paper-based strips deliver visual results in minutes without instrumentation, making them ideal for farm, warehouse, or border-inspection settings. The review highlights how nanomaterial labels, particularly gold nanoparticles, have transformed LFIA performance. A gold nanoflower-based LFIA for the herbicide acifluorfen achieved a detection limit of 7.79 nanograms per milliliter, 9.6 times lower than a conventional gold nanoparticle version. Time-resolved fluorescent microsphere-based LFIAs have pushed limits even lower, detecting the fungicide paclobutrazol at 1.72 nanograms per milliliter and providing results within 18 minutes for triadimefon residues in oranges, tomatoes, and cucumbers.

Immunosensors represent the most technologically sophisticated end of the antibody-sensing spectrum, coupling immunochemical recognition to electrochemical, optical, or microgravimetric transducers. Electrochemical formats dominate because they offer high sensitivity, portability, and low cost. A graphene oxide-decorated screen-printed electrode immunosensor detected aflatoxin B1 in wheat flour at an astonishing 1.26 femtograms per microliter. A smartphone-based magneto-immunosensor for the same toxin in corn extract achieved a detection limit of 24 picograms per milliliter, displaying results in a simple traffic-light format through a companion Android app. Nanobody-mediated FRET immunosensors have detected ochratoxin A in rice, barley, wheat, and oats within five minutes at sub-microgram-per-kilogram limits.

Despite these advances, significant hurdles remain. Matrix effects, in which naturally occurring compounds in fruits, vegetables, and cereals such as enzymes, lipids, pigments, and sugars interfere with the analytical signal, continue to plague antibody-based methods, causing signal suppression or enhancement that undermines accuracy. Researchers are countering this through optimized extraction protocols, including QuEChERS pretreatment, hexane cleanup, and careful buffer selection. Antibody stability during storage and repeated freeze-thaw cycles poses another challenge, with aggregation and denaturation eroding performance over time. Camelid-derived nanobodies offer a promising solution, retaining functionality at temperatures as high as 40 degrees Celsius where conventional antibodies would fail, making them especially valuable for on-site applications in resource-limited settings.

Looking ahead, the review points toward a hybrid future in which artificial intelligence amplifies the reach of antibody-based sensing. Connectionist machine learning models excel at extracting subtle patterns from raw sensor data, while symbolic AI frameworks provide the transparent, rule-based reasoning needed for regulatory compliance and traceability across food supply chains. Integrating smartphone readers, cloud connectivity, and AI-driven interpretation with LFIA and immunosensor platforms could automate result analysis, minimize human error, and enable real-time remote monitoring. As contamination pressures mount under climate change and intensifying agriculture, these antibody-powered technologies are poised to become an indispensable frontline defense in keeping the global food supply safe.

Subject of Research: Antibody-based biosensing technologies for detecting pesticide residues and mycotoxins in plant-derived foods

Article Title: Antibody-based sensing of pesticide residues and mycotoxins in plant-derived foods: A narrative review of ELISA, lateral-flow immunoassays and immunosensors

Article References: Kumar, H., Guleria, S., Peter, L., Akhtar, N., Asghar, R., Harun, H. B. C., Kumar, D., Kuča, K., Shaikh, A. M., Harsányi, E., & Kovács, B. (2026). Antibody-based sensing of pesticide residues and mycotoxins in plant-derived foods: A narrative review of ELISA, lateral-flow immunoassays and immunosensors. Food Chemistry: X, Article 104530. https://doi.org/10.1016/j.fochx.2026.104530

Image Credits: AI Generated

DOI: 10.1016/j.fochx.2026.104530

Keywords: ELISA, lateral-flow immunoassay, immunosensors, pesticide residues, mycotoxins, food safety, biosensors, nanoparticles, cereals, fruits and vegetables, nanobodies, food contamination

SVMPs belong to the metzincin superfamily of metalloproteases, a group that also includes the mammalian matrix metalloproteinases and the ADAM and ADAMTS proteins. What unites them is a conserved catalytic motif, HEXXHXXGXXH, which coordinates a single zinc ion essential for cleaving peptide bonds. When a viper strikes, these enzymes flood the victim’s tissues and begin systematically dismantling the extracellular matrix and basement membranes that hold blood vessels together. The result is the characteristic pathology of hemotoxic envenoming: capillary leakage, profuse local and systemic bleeding, edema, blistering and progressive necrosis. Because the enzymes are so efficient at degrading structural proteins such as collagen, laminin and perlecan, even relatively small amounts can destabilize the microvasculature within minutes of a bite.

The review emphasizes that SVMPs are not a single entity but a structurally diverse family classified into three principal classes based on their domain organization. P-I enzymes consist of a catalytic metalloproteinase domain alone, making them the simplest members of the family. P-II toxins add a disintegrin-like domain, which allows them to interfere with platelet aggregation by binding integrin receptors, while P-III enzymes carry additional domains, including cysteine-rich and C-type lectin-like regions, that expand their repertoire of interactions with host tissues. This modular architecture explains why SVMPs produce such a bewildering range of effects, from direct hemorrhage to inflammation, apoptosis of vascular cells and disruption of blood coagulation. It also means that a therapeutic strategy effective against one class may fail against another, a central challenge for anyone attempting broad-spectrum neutralization.

The molecular pathogenesis of SVMP-mediated damage has been worked out over more than half a century, beginning with early enzymatic studies of habu snake venom in the late 1950s and the landmark isolation of hemorrhagic toxins from western diamondback rattlesnake venom in the 1970s, which first established the critical role of zinc. Subsequent electron microscopy and biochemical work showed that these enzymes attack the basement membrane of capillaries, weakening the vessel wall until the sheer pressure of blood flow causes it to rupture. More recent studies have revealed additional layers of pathology: SVMPs such as jararhagin from Bothrops jararaca trigger the release of pro-inflammatory cytokines, recruit immune cells that contribute to necrosis, and induce apoptosis of endothelial cells through vascular apoptosis-inducing proteins identified in rattlesnake venom. Some members of the family also perturb the coagulation cascade, either degrading clotting factors or activating them inappropriately, compounding the bleeding disorder.

Against this backdrop, the limitations of conventional antivenom therapy loom large. Antivenoms, produced by immunizing horses or sheep with venom and purifying the resulting antibodies, remain the only approved treatment worldwide, and the World Health Organization classifies them as essential medicines. Yet they are expensive, require cold-chain distribution and hospital administration, and are most effective against systemic effects such as coagulopathy. Local tissue damage, which begins almost immediately after the bite, is often already irreversible by the time antivenom is infused. Antibody molecules also distribute poorly into peripheral tissues, leaving the very compartments where SVMPs inflict their worst damage relatively unprotected. These shortcomings have pushed researchers toward small molecules and engineered biologics that can be administered early, potentially even in the field.

The review surveys several promising classes of SVMP inhibitors. Plant-derived compounds have attracted particular attention, especially from research groups in regions where snakebite burden is highest. Flavonoids such as myricetin have been shown to inhibit venom metalloproteinases, while rosmarinic acid from Argusia argentea suppresses hemorrhage induced by habu venom, and gallic acid reduces the toxic activities of Bothrops jararaca and Bothrops jararacussu venoms. Lapachol analogs from plants have emerged as selective metalloprotease inhibitors active against Bothrops venom, and mango seed kernel extracts have demonstrated anti-SVMP activity supported by molecular docking studies. Ethnopharmacological approaches, including a recent combined computational and experimental evaluation of Plumbago zeylanica against Russell’s viper envenomation by members of the same Indian team, continue to feed candidate compounds into the pipeline, although the review notes that herbal remedies face significant hurdles on the path to clinical validation.

Synthetic and repurposed small molecules represent perhaps the most clinically advanced frontier. Zinc-chelating agents can strip the catalytic metal from SVMPs and have shown protection against the proteolytic, hemorrhagic and myotoxic activities of saw-scaled viper venom. The most striking example is varespladib, a drug originally developed for cardiovascular indications, which has been preclinically validated as an early-intervention treatment for hemotoxic snakebite and shown to protect against venom lethality in combination with broadly neutralizing human antibodies. Matrix metalloproteinase inhibitors designed for oncology, such as marimastat and prinomastat, display differential activity against the metalloprotease components of various snake venoms, and recent medicinal chemistry efforts have identified DC-174, a hydroxamic acid pre-candidate being developed as an oral snakebite treatment. High-throughput screening campaigns dedicated specifically to SVMP inhibitors are now systematically expanding this chemical space.

Biologics are advancing in parallel. Monoclonal antibodies raised against specific SVMPs, including mutalysin-II, atroxlysin-I and the hemorrhagic toxin HR1a from Protobothrops flavoviridis, have neutralized hemorrhagic activity in experimental settings, and phylogenetically conserved epitopes shared across SVMPs offer hope for antibodies with broad cross-species coverage. Even more striking are camelid-derived nanobodies, the tiny single-domain antibody fragments prized for their stability, tissue penetration and ease of bacterial production. A landmark study published in Nature in 2025 demonstrated a nanobody-based recombinant antivenom effective against cobra, mamba and rinkhals bites, and nanobodies targeting hemorrhagic and myotoxic components of Bothrops atrox venom have been developed independently. These recombinant platforms promise antivenoms that are more consistent, cheaper to manufacture and rationally designed against defined toxins rather than whole venom cocktails.

The review closes by highlighting technologies that could accelerate discovery across all these fronts. Snake venom gland organoids, first derived in 2020, allow researchers to culture venom-producing tissue in vitro, providing a renewable source of toxins for functional testing and a platform for CRISPR-based target validation. Artificial intelligence and machine learning are being deployed to mine venom proteomes, predict inhibitor binding and prioritize candidates for synthesis, while structure-based drug discovery and molecular docking continue to illuminate how inhibitors engage the catalytic zinc and surrounding substrate-recognition pockets. The authors argue that integrating these computational, biotechnological and pharmacological approaches offers a realistic path toward precise, broad-spectrum and affordable interventions against SVMP-mediated envenoming, a goal that could transform outcomes for the millions of people, most of them rural and impoverished, who suffer snakebites each year.

Subject of Research: Structure, pathogenic mechanisms and therapeutic inhibition of snake venom metalloproteinases

Article Title: Targeting snake venom metalloproteinases: structural diversity, molecular pathogenesis and therapeutic interventions

Article References: Dodakallanavar, J., Harish, D. R., Hiremath, K., Sampat, G. H., Patil, V. S., Mahadevamurthy, R. K., Ugare, S., Akula, K. K., & Manjunathachar, H. V. (2026). Targeting snake venom metalloproteinases: structural diversity, molecular pathogenesis and therapeutic interventions. Molecular Biology Reports, 53(1), Article 1619. https://doi.org/10.1007/s11033-026-12781-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12781-z

Keywords: snake venom metalloproteinases, SVMPs, snakebite envenoming, antivenom, zinc-dependent proteases, metzincins, small molecule inhibitors, nanobodies, recombinant antibodies, varespladib, venom gland organoids, structure-based drug discovery

Immunoaffinity chromatography occupies a special place in modern bioprocessing. By exploiting the exquisite specificity of antibodies for their antigens, it allows a desired protein to be pulled out of a complex mixture based on epitopes displayed on its surface, a capability that applies to nearly every antigen imaginable. Yet the technique is expensive and technically demanding at industrial scale, and its success hinges on the properties of the immobilized ligand. Conventional immunoglobulins are large, fragile molecules that can denature under the harsh acidic or alkaline conditions used to strip bound product from a column, shortening resin lifespan and raising costs. The variable domain of camelid heavy-chain antibodies, known as VHH or nanobody, has emerged as a compelling alternative. These roughly 15-kilodalton fragments are small, remarkably stable, and resistant to conditions that destroy ordinary antibodies, and they have already proven their worth commercially in resins such as the CaptureSelect family used across the biopharmaceutical industry.

Recombinant factor VII presents a particularly demanding purification challenge. The protein is expressed in baby hamster kidney cells and is both thermally sensitive and structurally fragile, requiring a rapid series of downstream steps to preserve its integrity. Because the drug is administered in its active form, activation at the end of the bioprocess is essential. At least one affinity chromatography step is indispensable, and the newest commercial solution, VIISelect from GE Healthcare, relies on a camelid VHH ligand discovered from an immune llama antibody library. Immune libraries, however, require animal immunization, a drawback that limits their use against toxic, poorly immunogenic, or otherwise unsuitable antigens. Synthetic libraries sidestep this limitation entirely, allowing binders to be discovered against an essentially unrestricted range of targets through rational design of molecular diversity.

The research team, led by Aliasghar Rahimian, Ali Nabati, Hooman Askari, and Mahdi Aminian, drew on two anti-factor VII nanobodies, designated VHH19 and VHH24, which they had previously isolated from a phage-displayed synthetic VHH library built on the cAbBCII-10 scaffold. This framework is prized for its exceptional stability, its plasticity for grafting diverse antigen-binding loops, and its acceptable expression yield in bacteria. The two binders carried affinity constants of 10 to the power of minus eight and 5.8 times 10 to the power of minus eight, respectively, indicating tight binding to the coagulation factor. The team expressed the nanobodies in the periplasm of TG1 bacterial cells on a five-liter scale, recovered them through osmotic shock, and purified them sequentially on nickel-affinity resin and Sephacryl S-100 gel filtration to remove aggregates and polymers. Yields reached approximately 0.8 milligrams per liter for VHH19 and 1 milligram per liter for VHH24, with reducing SDS-PAGE revealing the expected doublet of native and disulfide-reduced forms around 15 kilodaltons.

Before committing the binders to a column format, the researchers verified their specificity by enzyme-linked immunosorbent assay. Both purified VHHs produced strong, concentration-dependent signals on wells coated with recombinant factor VII, while signals on wells coated with diluted human blood plasma, used as a source of non-specific antigens, remained at baseline across all coating concentrations. This clean discrimination against the thousands of proteins present in plasma is a critical prerequisite for any ligand intended to purify a therapeutic protein from biological feedstocks. Encouraged by these results, the team coupled each nanobody to cyanogen bromide-activated cross-linked agarose beads, a classical chemistry that converts agarose hydroxyl groups into cyanate esters reactive with protein amino groups. By measuring protein remaining in the coupling supernatant, they determined that coupling efficiency exceeded 95 percent for both binders, yielding resins containing approximately 2 milligrams of immobilized VHH per milliliter of gel.

The decisive test came in column chromatography, where the chemistry of calcium binding to the Gla domain of factor VII shaped the optimization strategy. Calcium association is essential to the conformation and enzymatic activity of the protein, so the team screened four buffering systems that varied the presence of calcium chloride and EDTA during binding and elution. The outcome was unambiguous: only the VHH19-based resin, designated Seph4B-VHH19, captured factor VII effectively, and only when calcium chloride was present in the binding and washing buffers. Under those conditions the factor VII concentration in the flow-through was depleted almost completely, whereas procedures lacking calcium produced partial or negligible adsorption. EDTA proved unable to elute the bound protein, leaving acidic glycine-hydrochloric acid buffer at pH 2.2 as the effective desorption agent. The VHH24 column and an uncoupled control resin retained the protein poorly or not at all under every condition tested, and both were excluded from further study.

With the optimal conditions established, the researchers benchmarked their resin against the commercial VIISelect medium using breakthrough curve analysis on a partially purified, inactive factor VII feed. Seph4B-VHH19 processed 28 plus or minus 1 milliliter of feed before breakthrough, yielding 2.3 plus or minus 0.15 milligrams of eluted protein per milliliter of resin, compared with 42 plus or minus 1 milliliter and 4.08 plus or minus 0.06 milligrams per milliliter for VIISelect. The authors attribute roughly half of this capacity gap to ligand density: the commercial resin reportedly carries about 6 milligrams of ligand per milliliter, double the loading achieved with their research-scale periplasmic expression system. They argue the comparison should be read as a feasibility demonstration rather than a head-to-head performance contest, noting that industrial expression improvements and more sophisticated coupling chemistries could readily narrow the difference.

Two further results stand out for bioprocess engineers. First, the resin proved operationally robust: it performed consistently across four consecutive chromatography cycles, and although cleaning with 0.1 molar sodium hydroxide before a fifth cycle cost 15 percent of the dynamic binding capacity, the column retained that reduced capacity after a full month of storage at 4 degrees Celsius. The limited alkaline tolerance marks a clear target for future sequence optimization and cleaning-procedure refinement. Second, and perhaps more striking, the column accomplished on-column activation of the drug substance. When a mixture of partially purified inactive factor VII and human plasma was passed through Seph4B-VHH19, the resin excluded a substantial portion of the plasma contaminants, and the eluted factor VII appeared as two chains of 20 to 30 kilodaltons on reducing SDS-PAGE, the signature of autocleavage. Activity assays confirmed the transformation: eluate fractions reached 26.8 kilo-international units per milliliter, roughly two hundred times the 0.12 KIU per milliliter measured in the pre-column sample, while flow-through and wash fractions carried almost none of the activity.

This activation step matters because commercial factor VII production is not complete without it; in existing downstream processes, activation occurs as a byproduct of concentration during ion-exchange chromatography. The nanobody column reproduced that behavior naturally, concentrating the protein enough to trigger autocleavage as it bound. The authors place their work in a broader context of nanobody-based affinity media, which have already been engineered for demanding targets such as adeno-associated virus serotype 8 and for separating closely related product forms of low-abundance plasma proteins. Nanobodies resist aggregation because they lack the variable light-chain domain, their frameworks can be fully humanized, and the cAbBCII-10 scaffold offers exceptional plasticity for CDR grafting. The synthetic library approach eliminates animal immunization and permits rational targeting of difficult antigens, though the absence of in vivo affinity maturation means isolated clones may need additional in vitro optimization to match the affinity profiles of immune-derived counterparts.

The study also exposes a knowledge gap that the authors hope the field will fill. Few publications assess how different conjugation methods and linkers affect the performance of VHH affinity columns, and the cyanogen bromide chemistry used here, while simple and traditional, immobilizes ligands in random orientations. Site-specific immobilization strategies, including engineered tag systems, have been shown to improve both capacity and resin stability compared with random amine coupling, and the team has published the sequence of VHH19 to encourage such exploration. For an industry that already generates billions of dollars in value from VHH-based CaptureSelect resins, the demonstration that a fully synthetic, animal-free discovery pipeline can produce a functional purification ligand for a fragile, medically critical coagulation protein signals a practical new route to affinity media, one that could extend to toxic, poorly immunogenic, or otherwise inaccessible targets where immunized llamas simply cannot help.

Subject of Research: Synthetic camelid nanobody binders for immunoaffinity purification of recombinant coagulation factor VII

Article Title: Application of camelid nanobody binders derived from a novel full-synthetic VHH library in immunoaffinity purification of recombinant coagulation factor VII

Article References: Rahimian, A., Nabati, A., Askari, H., & Aminian, M. (2026). Application of camelid nanobody binders derived from a novel full-synthetic VHH library in immunoaffinity purification of recombinant coagulation factor VII. Heliyon, 12(15), Article e45524. https://doi.org/10.1016/j.heliyon.2026.e45524

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45524

Keywords: nanobodies, VHH, synthetic antibody library, coagulation factor VII, immunoaffinity chromatography, bioprocessing, hemophilia, affinity resin, phage display, recombinant protein purification, cyanogen bromide coupling, downstream processing

The core argument of the perspective is a reframing of what modern pathogen monitoring needs to achieve. For decades, the dominant measure of progress in detection technology has been analytical sensitivity, the ability to find ever smaller quantities of a target organism in a sample. The authors contend that sensitivity, while still important, is no longer the decisive bottleneck. In their view, the key challenge is no longer simply detecting pathogens with greater sensitivity, but increasing monitoring frequency and expanding surveillance from individual targets to multiple priority pathogens in near real time. In other words, a system that detects one pathogen exquisitely well, once a week, after samples have been shipped to a central laboratory, offers far less protective value than a system that watches many pathogens continuously at the point of concern.

The limitations the authors describe are rooted in the architecture of established microbiological methods rather than in any single technical weakness. Traditional culture-based methods, in which microorganisms are grown on or in nutrient media and identified by their growth characteristics, remain valuable in one crucial respect: they determine whether the microorganisms found in a sample are viable, or alive and capable of reproduction. That information matters enormously for risk assessment, because genetic material from dead organisms does not necessarily indicate an active threat. However, culture methods are slow, often requiring days of incubation, and they are poorly suited to organisms that are difficult to cultivate. They also demand trained personnel, laboratory infrastructure and physical sample transport.

Molecular approaches have transformed pathogen detection over the past several decades. Polymerase chain reaction, or PCR, amplifies specific genetic sequences so that tiny amounts of pathogen DNA or RNA can be detected with high sensitivity. Sequencing technologies go further, allowing detailed characterization of the organisms present in a sample, including the identification of strains, virulence factors and antimicrobial resistance genes. Yet the authors point out that even these powerful molecular tools commonly depend on sample collection, laboratory processing, specialized instruments and subsequent analysis. Each of those steps introduces delay, cost and logistical complexity, which together limit their usefulness for continuous, in situ monitoring, meaning monitoring performed directly at the site of the water body or water system being watched.

To bridge the gap between laboratory-grade analysis and real-time field surveillance, the perspective highlights several emerging technologies that the authors believe could serve as complementary layers in a redesigned monitoring architecture. The first is nanobody-based recognition coupled with fiberoptic sensors. Nanobodies are small, single-domain antibody fragments derived from camelid antibodies that retain antigen-binding capacity while being far smaller, more stable and easier to produce than conventional antibodies. When deployed on the surface of fiberoptic sensors, which convert biological binding events into measurable optical signals, they could enable rapid first-line screening of several predefined pathogens at once, acting as a broad biological tripwire that flags when any of a panel of priority organisms appears in the water.

A second technological layer involves functional nucleic acids, a class of synthetic molecules that includes aptamers and deoxyribozymes. Aptamers are short, single-stranded DNA or RNA sequences that fold into specific three-dimensional shapes capable of binding target molecules with antibody-like affinity and specificity. Deoxyribozymes, or DNA enzymes, are catalytic DNA sequences that can perform chemical reactions, including the sequence-specific cleavage of nucleic acid targets. In the surveillance framework proposed by the authors, these probes could provide a more specific secondary analysis, refining or confirming the preliminary signal generated by the first-line screening step. Because functional nucleic acids are chemically synthesized, they can be selected in the laboratory for virtually any target, are relatively stable, and can be regenerated or integrated into amplification schemes, characteristics that make them attractive for repeated-use sensing surfaces.

The third enabling technology is microfluidics, the engineering discipline concerned with manipulating small volumes of fluids through channels measured in tens or hundreds of micrometers. Microfluidic platforms could automate the sample handling steps that currently consume much of the time and labor in pathogen testing, and they could run many detection reactions in parallel on a single chip. By miniaturizing and integrating filtration, reagent mixing, splitting into multiple channels and signal readout, microfluidics offers a path toward devices that continuously process water samples and test them against an entire panel of pathogen targets without human intervention between sampling and result.

Bringing these components together, the authors sketch an end-to-end framework illustrated in the paper. Automated sampling draws water at regular intervals without an operator on site. Pathogen concentration steps overcome the fundamental dilution problem of environmental monitoring, in which even contaminated water may contain vanishingly few target organisms per liter. Multiplex recognition, the simultaneous interrogation of many targets, is then performed by the nanobody-fiberoptic and functional nucleic acid layers, followed by rapid signal detection, computational data analysis and, crucially, early warning: the automated flagging of results that meet predefined risk thresholds. Importantly, the framework does not discard the classical toolkit. Culture, PCR and sequencing remain available within the system for confirmation and deeper characterization whenever the rapid screening layer raises a flag, preserving the viability information and strain-level detail that only those methods can provide.

The authors are careful to emphasize that practical deployment will require far more than highly sensitive sensors, and this candor is one of the most valuable aspects of the perspective. Environmental water is a hostile medium for analytical instruments. Pathogen concentrations in real water bodies are typically very low, demanding extreme analytical performance. Water matrices are chemically and biologically complex, containing sediments, organic matter, salts and competing microorganisms that can interfere with recognition and signal transduction. Biofouling, the accumulation of microbial films on sensor surfaces, can degrade performance within days. Sensor drift, the gradual change in a device’s response over time, undermines the long-term comparability of measurements. Cross-reactivity, in which a probe binds unintended targets, threatens the specificity that multiplex panels depend on. Calibration across seasons and sites, and simply keeping instruments operating stably over months or years in the field, remain unsolved engineering problems that no amount of laboratory sensitivity can compensate for.

The vision that emerges is therefore not one of replacement but of complementarity. Rather than displacing established laboratory methods, the authors envision biosensors as tools that could shorten response times and strengthen early warning systems, forming a rapid outer ring around the slower but more definitive core of conventional analysis. If the engineering challenges they identify can be met, integrating these technologies into reliable multipathogen surveillance networks may materially improve aquatic biosafety, supporting faster management of waterborne biological risks and, ultimately, safer water for the communities that depend on it. The perspective, published as Li and colleagues’ article in Biocontaminant, offers researchers and water managers a candid map of both the promise and the unfinished work on the road to continuous, multipathogen monitoring.

Subject of Research: Real-time multipathogen biosensing for waterborne pathogen surveillance and aquatic biosafety

Article Title: From single-target tests to real-time multipathogen surveillance for safer water

Article References: From single-target tests to real-time multipathogen surveillance for safer water. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: waterborne pathogens, biosensors, nanobodies, fiberoptic sensors, aptamers, deoxyribozymes, microfluidics, PCR, sequencing, early warning systems, aquatic biosafety, water quality monitoring

Nanobodies, the single-domain antibody fragments originally derived from camelids, have become indispensable instruments across modern biology. Because they are compact, remarkably stable, and easy to engineer, they serve as conformational stabilizers, crystallization chaperones, biosensors, intracellular targeting agents, and imaging probes. Clinically, the class has already produced approved drugs such as caplacizumab, and nanobody-based therapeutics are advancing against cancer, autoimmune disorders, and infectious disease. In structural biology, their most celebrated role has been locking fragile membrane proteins into defined functional states, a strategy that made high-resolution structures of G-protein-coupled receptors possible more than a decade ago.

Traditionally, these binders are obtained by immunizing llamas or other animals with the protein of interest, an approach that fails when antigens are toxic, unstable, or require trapping in artificial conditions such as extreme pH or fully liganded states. Synthetic libraries sidestep these constraints entirely. Instead of an immune system, researchers use combinatorial gene libraries encoding billions of randomized antibody fragments, then select binders in vitro. Among the display technologies available, ribosome display is uniquely powerful because it couples each protein to its encoding messenger RNA without any cells, allowing theoretical diversities of 10^12 to 10^13 to be explored in a test tube, far beyond what phage or yeast display can practically achieve.

The existing benchmark, the Seeger concave sybody library, has enabled countless selections, including binders that trap membrane proteins in specific conformations. However, it carries a hidden incompatibility. Its nanobody constructs lack the C-terminal histidine tag that the Legobody system requires to recognize its target. Legobody, an approximately 120-kilodalton scaffold assembled from a sybody, an engineered maltose-binding protein, and a nanobody-binding antibody fragment, dramatically enlarges small protein complexes so that cryo-EM image alignment becomes feasible. Without the tag, every sybody recovered from the established libraries must be subcloned and re-engineered before it can be used, adding days of work and eroding throughput precisely where speed matters most.

The new S1.0 library eliminates that detour by embedding the required C-terminal histidine tag and a short Legobody-compatible linker directly into the library scaffold. But the redesign went beyond a simple tagging exercise. Drawing on structural analyses of published concave sybody-antigen complexes, the team noticed that these synthetic binders engage their targets mainly through the CDR1 and CDR2 loops, unlike natural nanobodies, which typically lean heavily on CDR3. In the concave library, the short seven-residue CDR3 and the largely fixed CDR1 had constrained where binding could occur. The researchers therefore extended CDR3 by one residue, raised the number of randomized positions in CDR3 and CDR1 to seven each, and deliberately reduced variability at one CDR2 position, restricting it to serine, tyrosine, arginine, and glutamate to tune surface chemistry while preserving the concave paratope architecture.

The mathematics of library design dictated careful restraint. Nineteen fully randomized positions would imply a theoretical diversity of roughly 5.2 × 10^24, unreachable by any physical display system. Instead, the team employed semi-randomization, enriching bulky aromatic and charged residues at positions likely to contact antigen while weighting choices according to amino-acid frequencies observed in natural nanobody interfaces, yielding a practical theoretical diversity of 10^18. The gene library itself was assembled through overlapping polymerase chain reactions, Type IIS restriction digestion, and T4 ligation, then transcribed into messenger RNA and stored in aliquots at minus 80 degrees Celsius.

Quality control came from deep sequencing. Approximately 9 × 10^7 reads of the naive library revealed that 98 percent of sequences were unique, and most designed amino-acid compositions at randomized positions matched expectations closely, particularly in CDR1, where 23 of 32 compositions showed discrepancies below 10 percent. Some positions, especially in CDR3, deviated more substantially, a caveat the authors acknowledge, though the overall fidelity confirmed that the construction strategy had faithfully captured the intended chemical space.

Functional validation proceeded against two test proteins. In head-to-head selections against calmodulin, performed in parallel with the benchmark concave library, S1.0 produced 45 positive clones from 96 screened, compared with 61 for the established library, but the S1.0 binders showed statistically significantly stronger calcium-dependent ELISA signals. Selections against thermostable green fluorescent protein, enzymatically biotinylated for magnetic bead capture, were even more striking: after one round of ribosome display and two rounds of phage display with off-rate selection, an enrichment factor of 427 was recorded, and ten unique sybody sequences emerged from twelve colonies analyzed. Fluorescence-detection size-exclusion chromatography showed that all ten shifted the elution profile of the fluorescent target, and biolayer interferometry confirmed nanomolar binding, with the best binder, named SH2, achieving a dissociation constant of 1.9 nanomolar.

The decisive experiment came next. When sybodies SH1 and SH2 were mixed with TGP and Legobody components, both assembled into stable complexes that could be pulled down through the maltose-binding protein’s affinity for amylose resin, detected directly by gel electrophoresis with no re-engineering of any kind. That intrinsic compatibility transforms the workflow for structural studies: a selection campaign that once ended with weeks of subcloning can now feed binders straight into Legobody assembly and cryo-EM grid preparation.

The authors are candid about remaining limitations. Validation covered only two soluble targets, and performance against the small membrane proteins that motivate the entire endeavor remains to be demonstrated. Sequencing also revealed instructive surprises, such as the strong underrepresentation of isoleucine at position 29 among functional binders despite its 20 percent abundance in the design, evidence that effective functional diversity, not raw theoretical diversity, ultimately governs library success. The team argues that accumulating sequencing data from naive and enriched libraries, mined with machine-learning approaches and shared through public repositories, should guide the next generation of synthetic nanobody libraries, turning empirical selection outcomes into ever-smarter designs.

Subject of Research: Design and validation of a ribosome display library for synthetic nanobody selection

Article Title: Design and validation of a ribosome display library for synthetic nanobody selection

Article References: Gu, W., Li, Y., Hong, J., Yue, Z., Zhang, Y., Fan, S., Shen, Z., Li, T., & Li, D. (2026). Design and validation of a ribosome display library for synthetic nanobody selection. Advanced Biotechnology, 4(2), Article 19. https://doi.org/10.1007/s44307-026-00112-z

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00112-z

Keywords: nanobodies, sybodies, ribosome display, synthetic antibody library, Legobody, cryo-EM, structural biology, membrane proteins, CDR randomization, biolayer interferometry, phage display, protein engineering

The significance of the finding lies in the peculiar architecture of NLRP3 itself. Like other members of the NOD-like receptor family, NLRP3 is built from a pyrin domain at its amino terminus, a central NACHT nucleotide-binding domain, helical domain 2, and a carboxy-terminal leucine-rich repeat region. Structural work over the past several years, including cryo-electron microscopy studies of full-length NLRP3, has revealed that in its resting state the protein folds back on itself into a compact, ADP-bound, cage-like conformation. The leucine-rich repeats wrap around the NACHT domain, and multiple intramolecular contacts lock the receptor into an autoinhibited state. This autorepression is essential for preventing spurious inflammation, but it also creates a puzzle: activating stimuli as chemically and physically diverse as nigericin, ATP, crystalline silica and imiquimod do not bind NLRP3 directly. Something else inside the cell must physically pry the receptor open, and until now, that something had not been convincingly identified.

To find it, the team took an unbiased approach. Using two complementary screening strategies, including mass spectrometry of ASC immunoprecipitates and insoluble complexes isolated from activated immune cells, they searched for proteins that associate with the NLRP3 inflammasome during activation. Among the hits that emerged was AMBRA1, short for activating molecule in Beclin1-regulated autophagy protein 1. AMBRA1 was already a familiar name in cell biology, having first been characterized as a regulator of autophagy and nervous system development, and more recently implicated in the control of D-type cyclins through cullin-RING ubiquitin ligase complexes. Its appearance in the NLRP3 proteome suggested an entirely unexpected second career for the protein. The researchers confirmed that AMBRA1 is a genuine constituent of the NLRP3 inflammasome complex, co-localizing with NLRP3 and ASC specks in stimulated cells.

The functional evidence was immediate and compelling. When the researchers deleted AMBRA1 from human THP-1 monocytic cells or from murine immortalized bone marrow-derived macrophages, NLRP3 activation collapsed. Cells lacking AMBRA1 failed to form ASC specks efficiently, showed reduced cleavage of caspase-1 and gasdermin D, and secreted far less interleukin-1β in response to nigericin, ATP and silica dioxide. Importantly, the defect was selective. Activation of the related NLRP1 inflammasome, triggered by the drug Val-boroPro, and AIM2 inflammasome activation induced by cytosolic DNA via poly(dA:dT) proceeded normally in AMBRA1-deficient cells, indicating that AMBRA1 is not a general requirement for inflammasome assembly but a specific cofactor for NLRP3. Reconstituting the knockout cells with full-length AMBRA1 restored inflammasome activity, cementing the causal relationship.

Delving into mechanism, the team demonstrated that AMBRA1 acts through direct physical binding to NLRP3. Using a combination of co-immunoprecipitation, in vitro protein interaction assays and fluorescence lifetime imaging microscopy-based Förster resonance energy transfer, they showed that AMBRA1 engages two specific subdomains of NLRP3: the leucine-rich repeat region and helical domain 2. The AMBRA1 surface responsible for this engagement involves its β-propeller domain together with an N-terminal helical region. Structural modeling, informed by AlphaFold 3-based predictions and supported by biochemical validation, revealed a large interaction interface burying roughly 3900 square angstroms of surface area, with the AMBRA1 β-propeller and N-terminal helix inserting into the concave face of the NACHT-LRR region of NLRP3.

The allosteric consequences of this binding are the heart of the discovery. By comparing structural models of AMBRA1-bound NLRP3 with the established inactive conformation, the researchers found that AMBRA1 engagement destabilizes the intertwined LRR assembly and promotes detachment of the interlocked NACHT subdomains. In other words, AMBRA1 physically pries apart the contacts that hold NLRP3 in its closed, ADP-bound, autoinhibited cage. Once the receptor is loosened, the nucleotide-binding pocket becomes accessible, and the team showed that AMBRA1 facilitates the binding of ATP to NLRP3. Nucleotide exchange and hydrolysis then drive the global conformational rearrangement that exposes oligomerization interfaces and the pyrin domain, allowing NLRP3 to multimerize, recruit the adaptor ASC, and launch the caspase-1 cascade. The authors draw an instructive parallel to Apaf-1, the apoptosome scaffold, which is likewise held inactive by an intramolecular interaction between its amino-terminal region and a WD40 β-propeller and is opened by binding of cytochrome c between its propellers. AMBRA1, in this scheme, plays a role for NLRP3 conceptually analogous to that of cytochrome c for Apaf-1, a conserved strategy of scaffold-mediated release from autoinhibition.

The study also clarified how AMBRA1 fits into the established, multistep model of NLRP3 activation. Prior work from the same collaborative group had shown that signal-induced phase separation of NLRP3 initiates inflammasome assembly, and other laboratories had defined roles for NEK7 licensing, trans-Golgi recruitment via phosphatidylinositol-4-phosphate, palmitoylation by ZDHHC enzymes, and deubiquitination by BRCC3. The new data indicate that AMBRA1 operates at the conformational opening step, acting as a scaffold that both promotes NLRP3 condensation and oligomerization and enables the transition to the ATP-bound active state. Genetic experiments showed that AMBRA1 deficiency did not disrupt upstream events such as priming of NF-κB signaling, dispersal of the trans-Golgi network, or lysosomal damage, pinpointing its action squarely at the level of NLRP3 itself. Notably, the interaction between AMBRA1 and NLRP3 was unaffected by the clinical-stage NLRP3 inhibitor MCC950, suggesting the two regulatory mechanisms are distinct.

The physiological stakes were tested in mouse models. Myeloid-cell-specific AMBRA1 knockout mice, generated using a Lyz2-Cre driver, showed markedly reduced inflammatory responses in three preclinical settings: endotoxic shock induced by lipopolysaccharide, dextran sulfate sodium-induced colitis, and polymicrobial sepsis. In the colitis model, animals lacking AMBRA1 in myeloid cells were protected from the weight loss and colon shortening that characterize the disease, phenocopying the protection seen in Nlrp3-deficient mice. These results position AMBRA1 as a genuine driver of NLRP3-dependent pathology in vivo, not merely a biochemical curiosity.

Perhaps the most translationally exciting aspect of the work is therapeutic. The team screened nanobodies, the single-domain antibodies derived from camelids, against AMBRA1 using a yeast surface display platform. Several nanobodies targeting the N-terminal helical region of AMBRA1, including Nb27, Nb14 and Nb35, blocked the AMBRA1-NLRP3 interaction and potently inhibited NLRP3 activation and interleukin-1β release in response to nigericin and to Salmonella typhimurium infection. Because the interface is a defined protein-protein contact rather than an enzymatic active site, it offers a structurally characterized target for small molecules or engineered biologics aimed at taming NLRP3-driven inflammation. Given the involvement of this inflammasome in gout, atherosclerosis, type 2 diabetes, Alzheimer’s disease, inflammatory bowel disease and sepsis, a validated molecular switch at the heart of NLRP3 activation could reshape the search for next-generation anti-inflammatory drugs.

The discovery also reframes AMBRA1 itself. A protein celebrated for coordinating autophagy initiation, dynein-dependent trafficking of autophagosomes and cyclin D degradation now stands revealed as a bifunctional regulator straddling two of the cell’s most fundamental stress responses: self-digestion and inflammation. How cells coordinate AMBRA1’s commitments between these pathways, and whether autophagy-related post-translational modifications tune its inflammasome-scaffolding activity, are questions the field will now pursue. What is already clear is that the autoinhibited cage of NLRP3 has a lock, and the key has finally been found.

Subject of Research: Allosteric activation of the NLRP3 inflammasome by the autophagy adaptor protein AMBRA1

Article Title: AMBRA1 allosterically activates NLRP3 by releasing its autoinhibition

Article References: Pan, M., Zhou, J., Fu, S., Tang, Y., Zou, G., Li, P., & Jiang, Z. (2026). AMBRA1 allosterically activates NLRP3 by releasing its autoinhibition. Nature Immunology. https://doi.org/10.1038/s41590-026-02644-x

Image Credits: AI Generated

DOI: 10.1038/s41590-026-02644-x

Keywords: NLRP3, AMBRA1, inflammasome, innate immunity, allosteric activation, autoinhibition, interleukin-1β, pyroptosis, autophagy, nanobodies, inflammation, sepsis